[1]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Carcinoma. Version 1.2023 [2]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Cancers. Version 2.2023 [3]FDA grants accelerated approval t...
NCCN(英文版)结肠癌2023.v2.pdf,® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Colon Cancer Version 2.2023 — April 25, 2023 NCCN.org ® NCCN Guidelines for Patients available at /patients Continue ® ® ® Version 2.2023,
修改为:et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplifed (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. J Clin Oncol 202...
the NCCN Guidelines recommend that all patients with recurrent or progressive cervical cancer be tested for PD-L1 expression. In addition, where possible, testing for DNA mismatch repair status (deficient vs proficient) and tumor mutational burden (TMB) is also recommended. Although they are rare,N...
In summary, the committee believes that a multidisciplinary approach is necessary for the management of the patient with colorectal cancer. The committee endorses the concept that treatment of patients on a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure...
NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 1:2012 Although colorectal cancer is a common malignancy, we have made little progress in its treatment. Several problems contribute to this situation. First, alt... AB Benson,JP Arnoletti,T Bekaiisaab,... - 《Journal of the...
2023 V1版NCCN指南解读 壶腹癌(Ampullary cancer)是指起源于Vater壶腹(壶腹、胆管十二指肠内部分和胰管十二指肠内部分)的肿瘤,而壶腹周围癌可能起源于包括胰头、远端胆管、十二指肠或Vater壶腹的位置。壶腹癌是罕见的消化道恶性肿瘤,仅占胃肠道恶性肿瘤的0.2%和所有壶腹周围癌症的6%,5年总生存率(OS)在35%...
2023 V1版NCCN指南解读 (Ampullary cancer)是指起源于(壶腹、胆管十二指肠内部分和胰管十二指肠内部分)的肿瘤,而壶腹周围癌可能起源于包括胰头、远端胆管、十二指肠或Vater壶腹的位置。壶腹癌是罕见的消化道恶性肿瘤,仅占胃肠道恶性肿瘤的0.2%和所有壶腹周围癌症的6%,5年总生存率(OS)在35%至50%之间。壶腹癌的...
Adjuvant Therapy for Colorectal Cancer Gets Revamp in NCCN GuidelinesWendling, P
personalizedtreatmentstrategiesforgastriccancer,butisnotcurrentlyrecommendedforclinicalcare.fSeePrinciplesofSurgery(GAST-C).gSeeNCCNGuidelinesforSmokingCessation.hSeePrinciplesofGeneticRiskAssessmentforGastricCancer(GAST-D).AlsoseeNCCNGuidelinesforColorectalCancerScreeningandNCCNGuidelinesforGenetic/FamilialHigh-Risk...